Travere Therapeutics completes sale of bile acid product portfolio to Mirum Pharmaceuticals.
Mirum has acquired Travere’s rights to Cholbam, indicated for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease, and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder, which is also under Phase III clinical evaluation for cerebrotendinous xanthomatosis (CTX)